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ABSTRACT
This thesis aims to evaluate the utility o f dynamic contrast enhanced computed 
tomography (DCE-CT) imaging in conjunction with kinetic analysis (CT Perfusion) 
for the investigation o f fibrotic liver disease. Monte Carlo simulations and sensitivity 
analysis o f the kinetic model were used to characterize the bias, variance and 
covariance o f perfusion parameters calculated with CT Perfusion. DCE-CT scans 
were performed on rats treated with carbon tetrachloride (CCI4) for 8 weeks to induce 
liver fibrosis, as well as sham injected control rats. Perfusion parameters were then 
derived from the DCE-CT scans using CT Perfusion. CCI4 treated rats showed 
significant changes in total hepatic blood flow, arterial hepatic blood flow, blood 
volume, and arterial fraction o f blood flow. Histological samples were collected at 
various stages o f  treatment and stained with methyl blue. Digital image analysis was 
used to quantify fibrosis content o f stained tissue. A strong correlation was found 
between fibrosis content and arterial fraction o f blood flow (r=.82 p<.00001).
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INTRODUCTION AND BACKGROUND TO HEPATIC FIBROSIS AND CHIRROSIS
1.1 INTRODUCTION TO THE LIVER
The liver is a vital organ that has many functions within the body. The primary 
functions include detoxification synthesis and production o f substrates necessary for 
metabolism o f lipids and carbohydrates. Situated in the upper abdomen behind the 
right ribcage and below the diaphragm, the liver blood flow is supplied by two 
sources (See Figure 1.1). The portal vein supplies blood from the spleen, gut and other 
mesentery, and accounts for approximately 75% of total liver blood flow. The 
remaining 25% o f liver blood flow is supplied from the hepatic artery ’. Owing to the 
higher oxygen content o f arterial blood, oxygen delivery to the liver is about equally 
derived from the portal vein and hepatic artery.
The liver plays an essential role in metabolism and has numerous roles in the 
body, including glycogen storage, decomposition o f red blood cells, plasma protein 
synthesis, hormone production, and detoxification. Unlike other organs, the liver 
benefits from a substantial regenerative capability. If as much as fifty percent o f its 
overall mass is surgically removed or damaged by intoxication, the liver is still 
capable o f complete regeneration . This regenerative ability makes the liver 
extremely resilient to toxins and disease, however, chronic liver injury over prolonged 
periods will result in the replacement o f normal healthy liver tissue with non­
functioning scar tissue (fibrosis) and reduced liver function. This scarring disrupts the
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normal liver architecture, leading to a resistance to blood flow through the liver. 
When the scarring progresses far enough that it encapsulates regenerating nodules o f  
liver parenchyma, the condition is referred to as cirrhosis. Cirrhosis is a potentially 
life-threatening condition with serious complications. The following section describes 
causes o f cirrhosis and its complications
1.1.1 Liver Disease
The Canadian Liver Foundation estimates that 3 million Canadians, including 
men, women and children, are currently living with some form o f liver diseases. The 
most common causes o f liver disease in Canada are listed below:
•  Viral infections such as hepatitis B, C and D virus (HBV, HCV, HDV)
• Non-alcoholic fatty liver disease
• Chronic alcoholism
• Genetic disorders such as hemochromatosis and Wilson disease
•  Autoimmune disorders such as primary biliary cirrhosis or primary sclerosing 
cholangitis
Treatment o f  liver disease can be labor intensive and costly 3. It is estimated that the 
annual cost to treat HCV infected intravenous drugs users alone, in Canada, is 
approximately $176,000,000. 4
No matter the etiology, the liver has a common innate wound healing response 
to chronic liver injury characterized by fibrosis o f the liver. If the cause o f the insult 
cannot be removed, fibrosis will progress to cirrhosis and eventually liver failure and
death.
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Normally blood flow from the intestines and spleen is pumped through the 
portal vein. The altered vasculature o f a cirrhotic liver presents a large resistance to 
blood flow. This resistance is measured as the pressure gradient between and the 
portal vein and the inferior vena cava, also known as the hepatic venous pressure 
gradient (HVPG). In a normal liver the HVPG is less than 5mmHg. A HVPG greater 
than lOmmHg is known as portal hypertension 5. The major complications o f portal 
hypertension are ascites, gastrointestinal hemorrhage and renal dysfunction.
Ascites is the accumulation o f fluid in the peritoneal cavity, driven by 
increased capillary hydrostatic pressure within the splanchnic bed as a result o f portal 
hypertension. Ascites carries a risk o f spontaneous bacterial peritonitis and sepsis. 
Diuretics can be used to control the accumulation o f fluids but as liver disease 
progresses this becomes more difficult6. Ascites and the abnormal handling o f sodium 
in combination with altered systemic circulation leads to hepatorenal disease 6. Liver 
transplant is the only long-term solution to hepatorenal disease, after which kidney 
function returns to normal or near normal leve ls.7
When the HVPG is greater than lOmmHg, blood flow though the hepatic 
portal venous system is redirected from the liver into areas with lower venous 
pressures. This means that collateral circulation develops in the lower esophagus, 
abdominal wall, stomach and rectum. The small, thin walled vessels become 
distended and are at risk o f rupture, causing the patient to bleed internally.
Portal hypertension and its complications are the leading cause o f morbidity
oand mortality in patients with cirrhosis.
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Hepatocellular carcinoma (HCC) is also a common complication for patients 
with liver disease. It has been estimated that 80% o f all HCC occurs in a cirrhotic 
background9. The annual risk o f developing HCC for patients with HCV infection has 
been estimated to be 3-8%9.
1.2 MICROSTRUCTURE OF THE LIVER
The hepatocyte is the primary parenchymal cell o f the liver, making up 80% of  
the total hepatic cell population. They are arranged in unicellular plates, sometimes 
referred to as Remak’s plates. These plates branch and anastamose with each other 
forming a maze like arrangement o f partitions. Between the plates o f hepatocytes are 
the liver sinusoids. Liver sinusoids can be regarded as unique capillaries. Unlike 
typical capillaries, the sinusoids have a discontinuous endothelial layer and lack a 
basement membrane 10. This endothelial layer is made up o f specialized liver 
sinusoidal endothelial cells (LSEC), which have groups o f fenestrations (pores) 
measuring 150-175 nm in diameter ". These fenestrations act as a dynamic filter for 
fluids, solutes and particles, allowing only particles smaller than the fenestrae to reach 
the parenchymal cell l0. Between the endothelial layer and the hepatocytes is the 
space o f  Disse. This space is primarily filled with hepatocyte microvilli as can be seen 
in Figure 1.2, which allows proteins and other components o f plasma to be absorbed 
by the hepatocytes. The hepatic stellate cell (HSC), also known as the Ito cell, 
lipocyte or fat-storing cells, resides within the space o f Disse. The HSC is the major 
cell type involved in the pathogenesis o f liver fibrosis, as is discussed in further detail 
in section 1.3. Kupffer cells are resident liver macrophages within the sinusoidal
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space where they can phagocytose and destroy foreign material such as bacteria.
Blood flow at the microscopic level originates at the portal triads. The portal 
triads consist o f an arrangement o f branches from the hepatic artery, portal vein, and 
bile duct, as well as lymphatic vessels. Blood supplied by the hepatic artery and portal 
vein passes through the sinusoids and empties into the central veins, which then 
coalesce into the hepatic veins. Figure 1.3 shows a representation o f the microvascular 
structure o f  the liver.
1.3 HEPATIC FIBROSIS AND VASCULAR REMODELING
A great deal o f progress has recently been made in understanding the 
pathogenesis o f  hepatic fibrosis. Fibrosis, or scarring o f the liver, is a wound-healing 
response that engages a range o f cell types and mediators to encapsulate injury. 
Although acute injury will activate mechanisms o f fibrogenesis, the sustained signals 
associated with chronic liver disease caused by infection, drugs, metabolic disorders, 
or immune attack are required for significant fibrosis to accumulate. Under certain 
circumstances a normal, or mildly fibrotic liver may rapidly progress to cirrhosis over 
several weeks or months. For example, patients with HCV receiving 
immunosuppressant drugs after liver transplant can have high viral load resulting in a 
rapid progression to cirrhosis . A similar situation exists in patients with human 
immunodeficiency virus (HIV)/HCV co-infection l3.
The hepatic stellate cell is the primary cell in the liver responsible for excess 
collagen synthesis during hepatic fibrosis14. Upon injurious stimuli the HSC
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undergoes ‘activation’ which is a complex transformation to a proliferative, 
contractile, myofibroblast-like cell. In reviewing the mechanisms o f hepatic fibrosis, 
Firedman S. defined three stages o f  fibrosis based on the activation o f stellate cells 15. 
These stages are initiation, perpetuation, and resolution. Initiating stimuli include 
paracrine signals such as reactive oxygen species from apoptotic hepatocytes, injured 
cholangiocytes, macrophages, stellate cells, and inflammatory cells 16 17. Early injury 
o f LSECs stimulates the production o f cellular fibronectin, as well as platelet derived 
growth factor (PDGF), which has an activating effect on stellate cells18. Apoptosis has 
also been implicated in the fibrogentic response19. Apoptotic proteins released from 
hepatocytes are fibrogenic towards cultured stellate cells20,21.
These initial parcrine signaling pathways result in changes in gene expression 
and phenotype allowing the now ‘activated’ HSC to respond to new stimuli leading to 
perpetuation. The induction o f type I collagen gene expression causes the HSC to 
become directly fibrogenic . In addition, PDGF and it’s receptor have been shown 
to be rapidly induced in culture and in vivo 24 25, resulting in proliferation as well as 
chemotaxis 26. The expression o f PDGF by LSECs along with the mitogenic effect of  
PDGF on HSCs results in an enhanced coverage o f sinusoids by HSCs in vivo .
Contractility is another key feature o f the activated HSC. HSC’s have been 
demonstrated to have contractile capability both in-vivo and in-vitro . This 
contractile capability is mediated primarily by endothelian-1 (ET-1) and inhibited by 
nitric oxide (NO) produced by LSECs 29 30. During liver injury, LSEC show impaired 
generation o f  NO resulting in vasoconstriction .
The combination o f proliferated HSCs covering the sinusoidal lumen, and their
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subsequent contraction from reduced NO production in LSECs, results in a 
constricted sinusoidal space. This alteration in the normal vascular structure, in 
combination with increased deposition o f collagen, contributes to increased 
intrahepatic sinusoidal pressure, portal hypertension, and it’s subsequent
• • 77 99complications
The activated HSC is not simply a fibrogenic cell, it also plays an important role 
in vascular structural changes and angiogenesis in hepatic fibrosis. Angiogenesis is 
the dynamic formation o f new vessels from pre-existing vessels 33,34. Angiogenic 
processes occur throughout the body and are associated with tissue damage, wound 
healing and vascular remodeling. Thus, it should come as no surprise that 
angiogenesis occurs concurrently with hepatic fibrosis. Stimulation o f angiogenesis 
during hepatic fibrosis is thought to come from several possible sources. Vascular 
endothelial growth factor (VEGF) is produced by hepatocytes in response to hypoxia
i f  'i f -as well as an autocrine signaling loop within LSECs . Activated HSCs have
• • ^ 7  "20also been shown to express angiogenic factors such as VEGF and angiopoietin-1 
HSCs and LSECs play a unique dual role in both fibrogenesis and angiogenesis as 
part o f  a total wound healing response. As a result anti-angiogenic drugs originally 
designed for cancer treatments have seen renewed interest for the treatment o f hepatic 
fibrosis and it’s complications. The inhibition o f the PDGF signaling pathway by the 
receptor tyrosine-kinase inhibitor Imatinib was capable o f  reducing portal pressure in 
an animal model o f  cirrhosis . Reduced portal pressure was primarily the result o f 
reduced sinusoidal coverage by HSCs, thus resulting in reduced constriction o f the 
sinusoids. Although portal pressure was reduced no reduction in fibrogenesis was
8
observed 27 39.
The resolution phase is still not completely understood. With the removal o f  the 
underlying cause o f liver injury, activated HSCs may revert back to a quiescent state 
or be cleared through an apoptotic pathway30. Reversibility o f  fibrosis and cirrhosis is 
still a debated topic but recently there has been increasing evidence that fibrosis and 
cirrhosis can resolve to at least some extent 40 41 42.
A strong motivation for the use o f perfusion imaging in hepatic liver disease is 
evident. The combination o f vascular remodeling and the role o f angiogenesis in the 
development o f cirrhosis mark it as a disease with significant vascular consequences. 
One direct consequence o f vascular changes in liver cirrhosis is portal hypertension. 
Portal hypertension is a major complication o f liver cirrhosis representing a primary 
cause o f  death or liver transplant 5 43. Currently the only measure o f portal 
hypertension is the HVPG. This technique is highly invasive and impractical under 
normal circumstances however, it is also currently the best predictor o f complications 
from cirrhosis and the development o f HCC 43 44. Non-invasive dynamic contrast 
enhanced magnetic resonance (DCE-MR) perfusion measurements have already been 
correlated to the HVPG in cirrhotic patients 45. Further research into perfusion 
imaging techniques may provide useful non-invasive biomarkers o f fibrotic liver 
disease. These biomarkers could be capable o f predicting disease outcome and aid in 
patient treatment planning.
1.4 HEPATIC CIRCULATION AND BLOOD FLOW REGULATION
9
Roughly 25% o f blood flow and 50% o f oxygen is delivered to the liver from 
the hepatic artery. The remaining 75% o f blood flow and 50% o f oxygen is supplied 
from the portal vein. Total Hepatic blood flow is estimated to be approximately 25- 
30% o f cardiac output. Normal changes to hepatic blood flow can result from a 
variety o f conditions. Exercise and sleep have been shown to cause a decrease in 
hepatic blood flow 46, while an increase in hepatic blood flow has been observed in 
the postprandial state 47. Finally, hepatic blood flow tends to decrease with increasing 
age 48.
Regulation o f blood flow in the liver is governed through three different sites. 
Arterial flow is controlled by terminal hepatic arterioles, which are richly supplied in 
smooth muscles cells. Portal flow is dependent on the flow in the supplying organs 
and thus, is determined by the arterioles o f these organs (eg. spleen and mesentery). 
Finally, liver sinusoids and terminal hepatic venules are a source o f intrahepatic 
resistance 47. Blood flow in the liver is influenced by both intrinsic and extrinsic 
mechanisms.
1.4.1 Intrinsic hepatic bloodflow regulation
In autoregulation, increased arterial perfusion pressure results in hepatic artery 
vasoconstriction, presumably because o f a myogenic response o f the arteriolar smooth 
muscle to stretch imposed by the increased perfusion pressure [REF]. Pressure-flow 
autoregulation in the hepatic arterial system exists to some extent in the postprandial 
liver, but probably not in the fasted liver 49 50. There is no evidence o f autoregulation
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in the portal venous system; instead o f  the nonlinear pressure-flow relationship 
associated with autoregulation, there exists a linear pressure-flow relationship51.
Changes in the composition o f  the portal venous and systemic blood 
composition affect liver blood flow. These changes include arterial hypoxemia 52, 
systemic hypercapnia 53, and alkalosis 54. Hepatic arterial blood flow is increased by 
decreased portal oxygen tension and pH 54.
A relationship between arterial and portal venous blood flow has long been 
known to exist. It was demonstrated that an occlusion o f the portal vein results in an 
immediate rise in hepatic arterial blood flow 55. This response o f increased hepatic 
arterial blood flow in response to a decrease in portal blood flow is called the ‘hepatic 
arterial buffer response’ (HABR) 56. Lautt et al. 57 suggested that a change in the 
concentration o f adenosine, a vasoactive molecule, was responsible for this 
relationship. Adenosine is released at a constant rate in the space o f Mall, which 
contains the hepatic arterioles and portal venules, and its concentration is regulated by 
washout into these vessels, principally the portal vein. Thus, a drop in portal blood 
flow would induce an increase in the local concentration o f adenosine, which would 
in turn increase arterial blood flow 57. Conversely, an increase in portal flow would 
increase clearance o f adenosine, causing arterial vasoconstriction. As further 
evidence, it has been shown in the rabbit that the adenosine receptor antagonist, 8- 
phenyltheophylline, inhibited this response while, the adenosine uptake inhibitor, 
dipyridamole potentiated the HABR . Although increases in hepatic arterial blood 
flow result only in a partial compensation for decreased portal flow, oxygen delivery 
is maintained, even in cirrhotic livers ,9. While portal perfusion has a large effect on
_
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arterial blood flow, the reverse is not true. Changes in hepatic arterial flow have not 
been shown to cause significant changes in the portal venous flow .
Despite identifying adenosine as the clear regulator o f the HABR, the exact 
cell type or site o f adenosine production, as well as the specific biochemical pathway 
have yet to be identified. It is suggested that the adenosine involved with the HABR 
and autoregulation is produced at a constant rate and secreted into the space o f Mall. 
This adenosine is most likely derived from demethylation o f S- 
adenosylhomocysteine, a reaction that is oxygen independent and is proposed to 
account for basal adenosine production in the heart60.
Although the exact site o f  interaction o f the hepatic artery and portal vein has 
not been identified, it is clearly occurring at a very localized level. Lobular changes in 
blood flow, due to selective ligation o f the portal inflow, clearly demonstrates this 61. 
When portal flow to a single lobe was reduced by ligation, an increase in portal flow  
occured in the other lobes. The ligated lobe showed an increase in arterial blood flow  
while the unligated lobes showed a decrease in arterial flow. This demonstrates 
lobular independence o f the HABR 61.
In patients with cirrhosis, the HABR is blunted . A reduction in portal 
perfusion due to increased intrahepatic sinusoidal resistance has been observed in 
cirrhotic patients . This sustained reduction in portal flow results in the continuous 
activation o f the HABR 64. Accordingly, the HABR could play a protective role in 
hepatic circulation by maintaining oxygenation65.
The continuous activation o f the HABR in patients with fibrotic liver disease 
provides a potential target for evaluating the stage o f liver disease as well as the risk
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o f complications. The continuous, adenosine mediated, activation o f  the HABR has 
been implicated in the development o f hepatorenal disease 66, which is a severe 
complication o f liver disease that can result in death. Currently, perfusion imaging 
techniques are the only non-invasive way to regionally measure hemodynamic 
changes in the liver that are consistent with the HABR. This thesis attempts to 
measure hemodynamic changes in a rat model o f liver fibrosis using dynamic contrast 
enhanced CT (DCE-CT) scanning or CT Perfusion.
1.4.2 Extrinsic hepatic blood flow regulation
Branches o f the vagus, splanchnic, and sometimes phrenic nerves enter the 
liver mainly in association with the blood vessels and bile ducts. The sympathetic and 
parasympathetic nerves form an intercommunicating plexus, which terminates on 
arterioles and venules. Functional vagal innervation does exist in the dog and 
influences regional distribution within the liver by exerting effects on presinusoidal 
sphincters 67, rather than by affecting total liver blood flow.
O f the systemic hormones, epinephrine is the most likely to attain vasoactive 
concentrations physiologically. Both alpha and beta-adrenergic receptors are present 
in the hepatic arterial bed, whereas only alpha receptors exist in the portal vasculature
/TO Thus, epinephrine injected directly into the hepatic artery initially induces 
vasoconstriction via the alpha receptors, followed by vasodilation mediated by the 
beta receptors; the portal bed only vasoconstricts in response to intraportal 
epinephrine.
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Glucagon causes a graded and long-lasting hepatic arterial vasodilation and 
can antagonize the hepatic arterial vasoconstrictor responses to a wide range o f  
physiologic stimuli, including stress-induced sympathoadrenal outflow 69. 
Angiotensin II evokes profound vasoconstriction o f both hepatic arterial and portal 
beds, together with a significant reduction in mesenteric outflow, and this translates 
into a substantial reduction in total liver blood flow 70. Vasopressin also induces 
marked splanchnic vasoconstriction; consequently, reduction in venous outflow into 
the portal system and a reduction in inflow resistance in the portal vasculature 
occurring after vasopressin administration make this hormone very effective in 
alleviating portal hypertension .
1.5 ANIMAL MODELS OF LIVER FIBROSIS AND CIRRHOSIS
Several experimental models o f hepatic fibrosis have been developed. These 
include chemically induced fibrosis using hepatotoxic agents such as carbon 
tetrachloride (CCI4) 72, dimethylnitrosamine 73 and thioacetamide 74, immunological 
damage , biliary fibrosis via common bile duct ligation , and alcoholic liver disease 
such as the Tsukamoto/French model in rats77.
Carbon tetrachloride is the most commonly used toxin-based experimental 
model o f  liver fibrosis. It can be easily administered to rodents by inhalation, gastric 
gavage, and subcutaneous or intraperitoneal injections 11. The trichloromethyl radical, 
a metabolite produced by cytochrome P450 in hepatocytes leads to lipid peroxidation 
and membrane damage , which results in acute centrilobular liver necrosis. CCI4
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models o f  liver fibrosis have the advantage o f being well characterized with respect to 
the histological and biochemical changes associated with injury, inflammation, and 
fibrosis77,78. A further asset o f CCI4 models for in vivo animal studies is the ability to 
elicit a predictable and reproducible response. The administration o f barbiturates in 
drinking water can enhance the activation o f cytochrome p450, enhancing CCI4 liver 
injury, and is a common method o f hastening the development o f fibrosis. With a 
combination o f barbiturates and CCI4 treatment, development o f fibrosis can occur in 
as few as four weeks, and cirrhosis as early as eight weeks.
CCI4 models do have limitations. First, there is no direct human disease 
counterpart , and second, there is a failure to progress to the development of  
hepatocellular carcinoma unlike the dimethylnitrosamine model o f fibrosis 79. 
Although depending on the requirements o f  the fibrosis model, lack o f cancerous 
progression could also be viewed as an advantage.
A combination o f CCI4 and the barbiturate, phénobarbital, are used in this thesis 
to develop fibrosis and cirrhosis in rats. A detailed description o f the methodology can 
be found in chapter 3.
1.6 NON-INVASIVE METHODS FOR THE INVESTIGATION OF 
HEPATIC FIBROSIS AND CIRRHOSIS
The current gold standard for assessing fibrosis is liver biopsy through a 
percutaneous, transjugular, laparoscopic, or fine-needle approach. This invasive 
method can be painful and carries a small but significant risk o f serious
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• 80complications . Further limitations come with the analysis liver biopsy samples. 
Histological grading is not reproducible; there are both intra- and inter-observer 
variability on small sized or fragmented biopsy samples . Because o f these 
limitations, biopsy is an impractical method for the regular monitoring o f liver 
fibrosis. As new anti-fibrotic treatments are developed, there is a growing need for 
non-invasive methods o f evaluating these treatments, as well as monitoring the 
progression o f hepatic fibrosis in patients. The most promising methods currently 
under development are reviewed below.
1.6.1 Serum indices
Serum markers can be divided into direct and indirect markers o f fibrosis. 
Direct markers are fragments o f  the liver matrix components produced by HSCs 
during the development o f fibrosis, and the molecules involved in regulating the 
progression o f fibrosis. These include hyaluronic acid, collagens IV and VI, and 
amino terminal fragment o f procollagen III. Indirect markers o f  fibrosis include 
molecules released into the blood due to liver inflammation, such as alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), molecules 
synthesised, regulated or excreted by the liver (such as clotting factors, cholesterol 
and bilirubin), and processes that become deranged as liver function becomes 
impaired, such as insulin resistance. Both direct serum markers, and indirect serum 
markers have been thoroughly investigated . When these markers are used
individually they can reasonably diagnosis or exclude cirrhosis but lack the ability to 
differentiate intermediate stages o f fibrosis. To increase diagnostic capability,
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algorithms combining multiple serum markers, such as Fibrotest or the Enhanced 
Liver Fibrosis (ELF) test have been proposed to improve diagnostic accuracy. In a 
meta-analysis Fibrotest was able to distinguish between METAVIR stages ^ 1  vs 
^F2 or ‘clinically significant’ fibrosis with area under the receiver operating 
characteristic curve (AUROC) o f .84 87. Currently, the ability to measure direct serum 
markers is not routinely available in most hospitals. Additionally, direct serum 
markers are not liver specific thus; they require patient specific considerations to be 
taken into account when interpreting the results.
1.6.2 Transient elastography
Transient elastography is performed with an ultrasound transducer probe 
mounted on the axis o f a vibrator. A vibration transmitted from the vibrator toward 
the tissue induces an elastic shear wave that propagates through the tissue. The 
velocity o f  the shear wave is then measured using pulse-echo ultrasound acquisitions. 
The harder the tissue, the faster the shear wave propagates 88. Transient elastography 
is advantageous in that it can be repeatedly performed, does not require a highly 
experienced operator, and has a low risk o f  complications. Results o f several recent 
studies have shown that measurement o f liver stiffness with transient elastography is 
excellent for the diagnosis o f cirrhosis, but lacks sensitivity and specificity for the
• OQintermediate stages o f  fibrosis . The reproducibility o f transient elastography is also 
substantially reduced in patients with steatosis and increased body mass index (BMI), 
as well as patients with ascities. This is because ultrasonography itself has limitations 
for clearly visualizing the liver in such patients. 90
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1.6.3 Magnetic resonance elastography (MRE)
MRE is a promising non-invasive method for monitor the progression o f liver 
fibrosis. MRE typically uses vibrations generated by external driver devices within 
the audio frequency range to induce shear waves in the liver. A signal generator 
triggered by and synchronized to the MR pulse sequence creates the electrical signal 
for these devices. A modified phase-contrast technique is used to image the 
propagation characteristics o f the acoustic shear waves 91 92. The technique is easily 
implemented on a conventional MRI system with modest additional hardware and 
software. Several studies have demonstrated the excellent diagnostic capability o f  
MRE to stage liver fibrosis 93 94 9S, but activity o f  the underlying cause and steatosis 
seem to influence measurements 95.
While MR elastography is a promising new method for staging liver disease it 
does not provide vital functional information about the liver. For the evaluation of  
new anti-fibrotic treatments a reduction in fibrotic content and reduced liver stiffness 
may not necessarily indicate successful treatment. For a patient with portal 
hypertension, a reduction in fibrosis content and liver stiffness is not clinically 
relevant unless it is accompanied by hemodynamic changes that alleviate the portal 
hypertension. Reversal o f  hemodynamic changes must accompany the reduction in 
fibrosis content for treatment to be completely successful.
1.6.4 Dynamic contrast enhanced computed tomography (DCE-CT)
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Dynamic contrast enhance computed tomography (DCE-CT) was developed in 
the late 1970s, with the aim o f studying hemodynamics in tissue 96. However, spatial 
and temporal resolutions o f early hardware limited the widespread acceptance o f  
DCE-CT. Advancements in CT scanning technology over the years has addressed 
these issues. The implementation o f slip ring technology has increased temporal 
resolutions to the sub-second mark. Detector technology has also progressed, allowing 
DCE-CT imaging o f  whole organs, such as the liver, in a single study. These 
advancements have allowed DCE-CT to become a more competitive imaging 
modality, as well as to gain wider clinical acceptance. Some o f the benefits o f  DCE- 
CT include its widespread availability in hospitals, its rapid scan times, with excellent 
spatial and temporal resolution, and its ability to image soft tissues, bone and blood 
vessels. Drawbacks o f DCE-CT include use o f contrast agents, which can impair renal 
function, and the exposure to carcinogenic ionizing radiation.
DCE-CT has become a valuable clinical and research tool in the study of 
angiogenesis and vascular changes associated with cancer and stroke diseases 97 98. 
Various methods have been developed to measure hepatic perfusion in vivo. These 
include Doppler ultrasound (US) 45, dynamic contrast enhanced magnetic resonance 
(DCE-MR)99 and DCE-CT 97. Compared to Doppler US, which is capable of  
measuring blood flow velocity in large vessels, DCE-CT is able to measure perfusion, 
blood volume, mean transit time, and capillary permeability surface area product in a 
single study97 In addition to this, DCE-CT can provide regional information that 
Doppler ultrasound can not. This set o f functional parameters provides a more 
complete evaluation o f tissue hemodynamics .
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The use o f MR as a modality for perfusion techniques seems appealing due to 
the lack o f  ionizing radiation. However, MR lacks a linear relationship between the 
concentration o f the gadolinium-based contrast agent and MR signal intensity. This 
fact along with velocity-induced signal intensity changes in larger vessels has created 
difficulties in obtaining quantitative perfusion data with DCE-MR 10°. In contrast, the 
relationship between iodine concentration and x-ray attenuation during DCE-CT 
examination is linear.
The maximum slope method for calculating liver perfusion is a commonly 
used method based on the Fick Principle 10°. If F is blood flow and Ca(t) is the contrast 
concentration at the arterial inlet and Cv(t) the contrast concentration at the venous 
outlet then:
QiT) = F - ) [ C „ - C ,} d t  (1)
0
Where Q(t) is the contrast concentration in the tissue at time T. If T is less than the 
minimum transit time o f the contrast agent through the capillaries, then one can 
assume no venous outflow and thus,
Q(T) = F-}c.-dt (2)0
or,
= F C a(T) (3)
The rate o f  contrast accumulation in the tissue, dQ(t)/dt, will be maximal when the 







The ratio o f  the maximum rate o f contrast accumulation, or maximum slope o f  
dQ(t)/dt to the maximum arterial concentration is equal to the blood flow.
The liver however, receives blood flow from both the hepatic artery and the 
portal vein, which further complicates the calculation. The tissue concentration curves 
from each blood flow source are overlaid, because the arrival o f  the contrast from the 
portal vein arrives seconds after the contrast from the hepatic artery. To separate the 
two concentration curves one can use the concentration curve from the spleen. 
Because o f the arrival time o f the contrast agent through the body, one can assume 
that peek enhancement o f the spleen occurs after the maximum rate o f change o f the 
contrast concentration in the liver tissue. Knowing this, the hepatic arterial blood flow  
can simply be calculated by the maximum slope o f the tissue concentration curve, 
before peak splenic enhancement, divided by the peak hepatic arterial concentration, 
Ca(t)max- Calculation o f portal perfusion is more complex because the initial slope o f  
the portal concentration curve is overlaid by the hepatic arterial concentration curve.
If one assumes that the liver and spleen show similar contrast agent dynamics 
during he arterial phase then the ratio o f the hepatic arterial blood flow to the splenic 
blood flow should be equal to the ratio o f their concentration curves. Hence, a model 
curve o f pure arterial hepatic enhancement is computed by multiplying the splenic 
time-concentration curve by the ratio o f  the maximum arterial liver gradient to the 
maximum splenic gradient o f the time-attenuation curves. This model curve is then 
subtracted from the original hepatic concentration curve, Q(t), resulting in a portal
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venous concentration curve o f the liver, Qpv(t), separate from its arterial component. 
Portal perfusion can then be calculated from dQpv(t)/dt divided by the the peak o f the 
portal venous concentration curve Cpv(t).
The maximum slope method has two main drawbacks. First the no venous 
outflow assumption may not always hold true, especially in a cirrhotic liver, which 
can have substantial shunt formation 101. Second the use o f the splenic concentration 
curve to model the hepatic arterial concentration curve has not been validated.
CT Perfusion (GE healthcare) is a commercially available software package 
capable o f analyzing DCE-CT datasets. It has been validated in the rabbit liver using 
radioactive microspheres as the gold standard 102, as well as in brain tumor 103 and 
VX2 thigh tumors104.
With its ability to assess hemodynamics in a non-invasive fashion, DCE-CT 
offers a way o f tracking the progression o f  hepatic fibrosis and cirrhosis in vivo 102. 
This thesis attempts to evaluate the utility o f  DCE-CT coupled with CT Perfusion in 
the assessment o f fibrotic liver disease. This is done using Monte Carlo simulation 
techniques as well as correlating CT Perfusion parameters to fibrotic content in a CCU 
rat model o f  hepatic fibrosis.
DCE-CT studies were performed on rats with a clinical multi-slice CT scanner 
(Discovery VCT, GE Healthcare). At DCE-CT examination, an iodinated contrast 
agent is injected via a peripheral vein while the CT scanner is used to measure the 
passage o f contrast through the vasculature and the uptake o f contrast in the 
extravascular (Disse) space, followed by the subsequent washout. In the analysis o f  
the DCE-CT data there are two fundamental underlying assumptions. The first is that
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the iodinated contrast agent is uniformly distributed throughout the vascular system 
and the second is that the enhancement (increase in attenuation) o f a particular tissue 
is proportional to the concentration o f the contrast agent in the tissue.
A localization scan was first performed to place eight 5mm slices covering the 
entire rat liver. After the scan location was selected the DCE-CT scan was conducted 
in two phases. In the first phase, images were acquired in cine mode under breath hold 
by turning o ff the ventilator with a tube voltage and current o f 120kVp and 80mA 
respectively and a gantry speed o f one rotation per second. Images were reconstructed 
using the detail reconstruction filter and a temporal resolution o f 0.45 seconds. Total 
time for the first phase cine scan was 34 seconds. In the second phase the ventilator 
was turned on with a breath rate o f 80 breaths per minute and animals were scanned in 
cine mode for 1.2 second, every 10 seconds, up to a total o f  two minutes. This two 
phase scanning protocol was designed for imaging a ventilated rat under ‘forced’ 
breath hold in the first phase by turning o ff the ventilator and ventilated breathing in 
the second phase. Chapter 3 gives further detail on animal procedures as well as the 
registration o f the second phase images.
The acquired two phase DCE-CT data were analyzed with CT Perfusion 
software (GE Healthcare) to derive quantitative maps o f total hepatic blood flow (F t ), 
hepatic arterial blood flow (Fa), blood volume (Vb), mean transit time (Tc), 
permeability surface area product (PS), as well as the hepatic arterial fraction o f blood 
flow a.
When a bolus o f contrast agent is injected into a peripheral vein, the rate o f  
delivery o f contrast agent to the capillary network in a unit mass o f  tissue is
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FT-[aCa(t)+(l-a)C pv(t)], where FT is total liver blood flow in ml/min per unit mass o f  
liver tissue and aC a(t)+(l-a)C pv(t) is a weighted sum o f the contrast concentration 
over time in the hepatic artery (Ca) and portal vein (Cpv) with the a  being the fraction 
o f Ft that is derived from hepatic artery. If the mass o f contrast in tissue (vessels plus 
Disse space) is linear with respect to the arterial concentration and Ft remains 
constant in time, then the following relationship holds true as a result o f  linear 
superimposition:
where Q(t) is the concentration o f contrast in tissue over time, R(t), is the impulse 
residue function (IRF), and * is the convolution operator. Q(t), Ca(t), and Cpv(t) in 
equation (5) can be measured by dynamic CT scanning as described previously and 
deconvolution between these two curves then yields FT-R(t), the flow-scaled impulse 
residue function (See Figure 1.4). R(t) describes the mass o f contrast that remains in 
the tissue following bolus injection o f a unit mass o f contrast l05. The algorithm used 
in CT Perfusion for the calculation o f the functional parameters is based on the 
adiabatic approximation o f the Johnson-Wilson model, a hybrid compartment and 
distributed parameter model with bidirectional exchange o f contrast between the 
intravascular space and the extra vascular space 106 107. The adiabatic approximation 
assumes that the tracer concentration in parenchymal tissue changes slowly relative to 
that in hepatic sinusoids. This assumption allows for a closed-form mathematical 
solution to the flow-scaled impulse residue function, FT-R(t) where R(t) is defined by :
(5)
R(t) = - 1.0
E e - « - ^
1
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0 < t< T a
T0< tc <Ta + Tc (6)
t >T0 + TC
By definition, Fx-R(t) is equal to Fx(ml/min/100g) from time zero to the (vascular) 
mean transit time, Tc, E is the extraction fraction 108 and k is FTE/Ve (where Ve is the 
distribution volume o f contrast in the Disse space). The area under the rectangular 
portion o f the blood flow scaled IRF corresponds to the blood volume (Vb, ml/lOOg). 
Fa, the hepatic arterial blood flow is then calculated as oc-Fx while the permeability 
surface area product o f  the liver sinusoids (PS) is calculated via the Renkin and Crone 
relationship. PS=-Fln(l-E).
The calculation o f perfusion parameters (T0, Ft, Vb, Fa and PS) described 
above is applied to the unique tissue enhancement curve Q(t) corresponding to each 
voxel in the DCE-CT time series. The model is fit to the measured Q(t) by searching 
all parameter values and minimizing the sum o f squares deviation. All parameter 
values are constrained to be positive, a  and E are fractions and are constrained to be 
between 0 and 1. Values for the calculated perfusion parameters are then assign to 
voxels corresponding to the Q(t) from which they were derived. This process 
generates a two-dimensional functional map for each perfusion parameter 
corresponding to each slice o f the liver in the DCE-CT scan. These maps are 
displayed as false color images from low (blue) to high (red) functional values.
CT Perfusion is a useful tool in the study o f vascular and angiogenic changes 
that occur in hepatic fibrosis and cirrhosis. It provides a non-invasive means to track
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changes in the development o f liver disease, and can aid in assessing the effects o f  
treatment as well as prediction o f clinical outcomes.
1.7 REASEARCH GOALS
The aim o f this project was to evaluate the utility o f  CT Perfusion in the 
investigation o f fibrotic liver disease. In this regard the three primary goals o f this 
thesis were as follows:
(1) Characterize the bias, variance and covariance o f perfusion parameter estimates 
associated with the CT Perfusion software package.
(2) Track changes in perfusion parameters during the progression o f fibrotic liver 
disease in a rat CCI4 model o f  liver fibrosis.
(3) Correlate perfusion parameters in rats measured with CT Perfusion to hepatic 
fibrosis content at various stages o f  liver disease.
1.8 THESIS OUTLINE
Chapter 2 presents a study investigating the CT Perfusion software package in 
terms o f the bias, variance and covariance associated with the perfusion parameters 
estimated. Three different parameter sets corresponding to normal, mild and severe 
liver disease were used for simulation. My contributions to the study were the 
determination o f parameters sets used, the completion o f all mathematical
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calculations, setup and running o f the Monte Carlo simulations, all subsequent data 
analysis and interpretation, and the writing and revision o f the manuscript.
Chapter 3 presents a study investigating changes in perfusion parameters in a 
rat CCI4 model o f liver fibrosis in comparison to a control group. Perfusion 
parameters were also correlated to histology. My contributions to this work were as 
follows; the handling and treating o f the animals with the assistance o f a trained 
animal technician; the conducting o f all DCE-CT examinations and subsequent image 
registration; analysis o f the DCE-CT scans with CT Perfusion; performing analysis on 
the derived functional maps; performing analysis o f  histological samples; statistical 
analysis; writing and revising the manuscript.
Chapter 4 provides a summary o f the findings from chapter 2 and chapter 3, 
followed by concluding remarks and suggestions for future work on the evaluation o f  
anti-fibrotic treatments and management o f fibrotic liver disease.
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Figure 1.1. Gross anatomy o f the gut showing the hepatic artery (red) as well as 
the portal vein and supplying vessels (blue). The portal vein supplies blood from the 
spleen, gut and other mesentery, and accounts for approximately 75% o f total liver 
blood flow. The remaining 25% o f liver blood flow is supplied from the hepatic 
artery. Grey's Anatomy. Vein: Hepatic Portal Vein. 28 March 2011. 
<http://upload.wikimedia.Org/wikipedia/commons/3/33/Gray591 .png>
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Figure 1.2. Sinusoid o f a rat liver with fenestrated endothelial cells. Fenestrae are 
approx 100-175nm in diameter, and sinusoidal width 5 microns. Original mag 30,000. 
Note the hepatocyte microvilli occupying the space o f Disse. Prof. Robin Fraser. 









Figure 1.3 The hepatic lobule. Blood flows from the portal triad (hepatic artery, 
portal vein, bile duct) through the liver sinusoids to a hepatic venule. (Adopted from: 
Cunningham, C.C., and Van Horn, C.G. Energy availability and alcohol-related liver 
pathology. Alcohol Research & Health 27(4):281-299, 2003.)
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-k(t-To-Tc)
Figure 1.4. The blood flow scaled impulse residue function (IRF) according to the 
Johnson-Wilson model with adiabatic approximation. Ft (ml/min/100g) is the blood 
flow, Vb (ml/100g) is the blood volume (shaded area), E is the extraction efficiency, 
Tc (seconds) is the mean transit time, k is the net back flow rate o f the contrast from 
the extravascular (Disse) space to the intravascular space.
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ERROR ANALYSIS OF HEPATIC PERFUSION PARAMETERS 
CALCULATED WITH CT PERFUSION
2.1 INTRODUCTION
In the past, fibrosis and cirrhosis were thought to be irreversible. Newer 
understanding o f the pathogensis o f hepatic fibrosis1,2 has resulted in many potential 
anti-fibrotic drugs such as the dual endothelin receptor antagonist, Bosentan. In order 
to test the efficacy o f potential anti-fibrotic drugs, a non-invasive measure o f fibrosis 
in animal models and eventually human clinical trials will be required.
The progressive breakdown o f normal vascular structure in a cirrhotic liver is 
associated with an increase in intrahepatic vascular resistance. Consequentially a 
change in both regional and global perfusion takes place in the liver 3'4. Patients with 
cirrhosis have been shown to have a decrease in portal hepatic blood flow (PHBF). 
The decreased portal perfusion is thought to be partially balanced by an increase in 
arterial hepatic blood flow (AHBF) via the hepatic arterial buffer response (H A B R )5. 
Lautt et. Al. originally demonstrated the HABR in the liver o f cats. Richter et. al. 
demonstrated this process in normal and cirrhotic rat livers and Aoki et. al. later 
demonstrated it in normal and cirrhotic livers o f humans. If PHBF and AHBF can be 
measured non-invasively, then the change in the ratio o f PHBF and AHBF could 
provide a non-invasive bio-marker for hepatic fibrosis.
Liver perfusion has previously been measured with dynamic PET methods 67.
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To properly estimate both PHBF and AHBF a dual input model must be used, 
requiring arterial and portal time activity curves. Due to the poor spatial resolution o f  
PET images, the portal activity curves cannot be obtained in a non-invasive manor 6.
Doppler ultrasound has also been investigated as a non-invasive method o f  
measuring hepatic blood flow 8. Doppler ultrasound measures the average velocity o f  
blood (cells) in a vessel, then flow is calculated using an estimate o f  the cross 
sectional area o f the vessel. This leads to two o f the major drawbacks o f using 
Doppler ultrasound. First, blood flow can only be calculated in large vessels, so no 
regional blood flow information can be obtained. Second, the measure o f the cross 
sectional area depends highly on the skill o f the operator, which leads to large intra­
observer variability 9.
Both dynamic contrast enhanced computed tomography (DCE-CT) and 
magnetic resonance imaging (MRI) offer greatly improved resolution over 
radioisotope techniques, eliminating the need for invasive portal venous 
measurements. Completely non-invasive measurements o f hepatic perfusion can be 
made and have been shown to correlate well with the severity o f cirrhosis 8,10,1'. MRI 
has the advantage o f not exposing patients to potentially harmful ionizing radiation, 
however, the non-linearity between contrast agent concentration and MRI signal poses 
problems for quantification.
Using either MRI or CT, several different methods o f analysis have been 
investigated. Miles et al 199310 proposed a simple method o f measuring blood flow  
based on the maximum slope o f the tissue time density curve (TDC) divided by the 
peak arterial concentration. Blomley et al 1995 reported a modified version that
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measures portal venous perfusion by subtracting the splenic time density curve, scaled 
to represent hepatic arterial flow, from the liver tissue curve. As previously pointed 
out 13 14 15 16 the maximum slope method has two shortcomings. First, the method 
assumes no venous outflow o f contrast at the time o f maximum initial slope, which 
may not always be true especially in liver disease. Second, modeling techniques allow 
for the measurement o f additional parameters. The maximum slope method only 
determines arterial and portal venous perfusion, whereas modeling methods can 
measure additional parameters such as mean vascular transit time (Tc), vascular 
volume and permeability surface area product (PS). These additional parameters may 
offer further insight into the development and progression o f liver disease.
Matem et al. proposed a dual input compartmental model to estimate both 
arterial and portal hepatic perfusion. However to achieve the perfusion estimates they 
assume that the extraction fraction, E, is simply 1.0, meaning that there is no barrier to 
diffusion between the vascular space and the Space o f Disse. This assumption is 
justified by the fenestrated endothelium o f  the liver sinusoids, allowing contrast agent 
to freely diffuse into the extravascular space (EVS). In the normal liver this 
assumption may be correct, however, capillarization o f the sinusoids has been 
reported in liver fibrosis and cirrhosis 17, which could limit the extraction o f contrast 
agent to the EVS to a varying degree.
The Johnson and Wilson two-compartment model is a good balance between 
mathematical complexity and accuracy . A time domain solution (the adiabatic 
approximation) has been proposed and thoroughly investigated for application with 
oxygen labeled water in the brain as well as treatment planning in stroke with regular
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CT contrast 19 20. This model has recently been modified for use in the liver by 
incorporating a dual blood flow source, allowing for the measurement o f both PHBF 
and AHBF, and validated using microspheres in rabbit liver with excellent results 15. 
In contrast to the dual input model proposed by Matem et al., the dual input Johnson 
and Wilson model makes no assumptions on the value o f the extraction fraction.
In this study we conduct a sensitivity analysis o f the model utilized in CT 
perfusion (GE Healthcare), as well as Monte Carlo simulations, to investigate the 
software’s utility in the investigation o f fibrotic liver disease in a rat model. We 
consider the normal, mild, and severe stages o f liver disease. Hepatic arterial and 
portal venous input functions used in the analysis and simulations were obtained from 
actual DCE-CT studies on rats.
2.2 METHODS
2.2.1 Tracer Kinetics Model
Simulations were conducted using CT Perfusion (GE Healthcare). The software 
utilizes the adiabatic approximation to the Johnson and Wilson model 18 described by 
St. Lawrence and Lee 19. A schematic o f the model is shown in Figure 2.2, where Ft is 
the total hepatic blood flow, Vb is the liver blood volume, Ve is the distribution o f  
contrast in the extravascular space o f the liver (Space o f Disse) and PS is the 
permeability surface area product o f  the endothelium o f liver sinusoids. The adiabatic 
approximation solution for the impulse residue function, R(t), o f the Johnson and 
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-PS/where E is the extraction fraction21 defined as, E = l - e  ' Ff, k=FTE/Ve is the rate 
constant o f  the washout o f contrast from the EVS to the intravascular space (IVS), To 
is the time delay between the arrival o f  contrast at the hepatic artery (or portal vein) 
and the liver, and Tc is the mean transit time o f contrast through the liver vasculature.
For organs with a single blood flow source, such as the brain, the tissue time 
density curve, Q(t), is defined by Equation 2 l9. F is the blood flow and C(t) is the 
time density curve o f the supplying vessel.
gtt)=Fc(f)*m  (2)
For the liver, which derives its blood flow from both the hepatic artery and the portal 
vein, Q(t) is the sum o f the enhancement from both blood flow sources. Thus, Q(t) for 
the liver becomes:
C*)='v <:„(/).«(0 (3)
Where Fa and Ca(t) are the AHBF and the hepatic artery time density curve 
respectively. Likewise Fpv and Cpv(t) are PHBF and the portal vein time density 
curve. R(t) is the same for both Fa and Fpv since the same unit o f tissue will have the 
same impulse response function. Equation 3 can be re-written in terms o f total blood 
flow to give Equation 4.
QV) = Ft- [aC„(0+(l-a)C^(0]*/!(<) (4)
Where Ft is the total hepatic blood flow and a  is the fraction o f total hepatic blood
□flow from the hepatic artery.
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2.2.2 Sensitivity Analysis
Sensitivity analysis provides a more in-depth understanding o f the tracer 
kinetics model. We calculate the sensitivity functions o f each parameter using 
Equation 5 where, SFI is the sensitivity function for the ith model parameter Pt.
□
SF = M )æ (5)□
Each sensitivity function represents the changes in the model output, namely the 
tissue time density curve (Q(t)), from a small change in the respective parameter. The 
greater the magnitude o f a parameter’s sensitivity function, the more sensitive the 
model output (Q(t)) is to a small change in that parameter and the estimation o f that 
parameter is less affected by noise in Q(t). Also the more similar the sensitivity 
functions o f  two parameters are the harder it is to separate the parameters.
2.2.3 Covariance/Correlation Matrix
Calculating the covariance (COV) matrix is important in understanding the inherent 
variance associated with estimating each o f  the model parameters. The COV matrix 
was calculated from the Fisher information matrix, F , as explained by Huang and 
Phelps and similarly used by Henderson et. al .
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The covariance matrix is:
c o v ^ ^ - F Ï  (7)
where ct is the estimate o f the noise variance in the measured model output, Q(t).
The diagonal elements o f the covariance matrix are the variances ( of i=Ft, a , 
E, k, To and Tc) o f the estimated parameters from the model. The o ff diagonal 
elements are the covariances (ajjij=FT, a , E, k, T0 and Tc) o f two estimated
parameters. The covariance matrix can be converted into the correlation matrix
P = - ^u a ai j (8)
Elements o f  the correlation matrix are all between -1 and 1. Unity represents 
perfect positive correlation and -1 is perfect negative correlation. A coefficient o f zero 
represents no correlation. The correlation matrix allows for an easier interpretation of 
parameter interactions.
2.2.4 Monte Carlo Simulation
Three different states o f  disease severity were considered for simulation. Table 1 
lists the parameter values for normal, mild and severe liver fibrosis. The values for a ,
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F, E, k, T0, and Tc were estimated from microsphere experiments and indicator 
dilution techniques in rats 24 25 26. Total hepatic blood volume, Vb and PS were derived 
from the assumed parameter values as Vb= F T c according to the Central Volume 
Principle 27 28 and PS=-Frln(l-E) from the Crone relationship 21. Using the assumed 
parameter values o f each disease state, along with the arterial and portal venous time 
density curves in Figure 2.1, the tissue TDC, Q(t), can be calculated using Equation 1 
and Equation 4. Gaussian random noise, which standard deviation was equal to the 
square root o f Q(t), was added to the tissue TDC.
For each disease state a time series o f  simulated CT images were generated from 
the simulated noisy curves o f the corresponding tissue TDC. Each set o f images 
consisted o f a 48x48 pixel block where the time density curve o f a pixel was a 
simulated noisy curve o f  the corresponding tissue TDC. CT Perfusion was used to 
analyze each set o f images to estimate the different parameters and their differences 
from the ‘true’ values. This method resulted in the equivalent o f 2304 simulation runs 
per simulated tissue TDC. From this data the variance and bias o f  each estimated 
parameter was determined.
3.3 RESULTS
Figure 2.3 shows the sensitivity functions calculated from Equation 1 for each 
parameter o f  the model as well as for each disease condition, normal, mild, and 
severe. Total blood flow was the most sensitive parameter followed by a , k, E, Tc, 
and To respectively. The sensitivity o f total blood flow increased with increasing
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disease severity while the sensitivity o f a  decreased. E and k both exhibited low 
sensitivity in the first 30 seconds, followed by increased sensitivity in the later phase. 
The mean transit time, Tc, showed decreasing sensitivity with increasing disease 
severity. The sensitivity o f To showed little change with disease severity.
Table 2 lists the variances o f  the estimated model parameters under normal, 
mild, and severe disease conditions, as determined from the diagonal o f  the 
covariance matrix. The variances o f Vb and PS were calculated from those o f other 
parameters using standard error propagation techniques. As disease severity increased 
all estimated parameters showed a decrease in their variation except a , which showed 
a slight increasing trend.
The correlation matrix was calculated for each disease severity and is shown in 
Table 3. (a ) was highly correlated with To for normal and mild disease states as well 
as Ft for mild and sever disease states. The highest correlations were observed 
between Ft and Tc as well as between E and k.
Figure 2.4 show the results from the Monte Carlo simulations. The bias is 
plotted on the vertical axis and standard deviation o f the added Gaussian noise on the 
horizontal axis. Error bars represent the standard deviation o f the estimated biases at 
each level o f noise. To and Vb showed little change in bias for both increasing noise 
and disease severity. Bias remained stable for Tc and Ft estimates for the mild and 
severe disease states but increased with noise for the normal disease state. The 
accuracy o f  parameter estimation amongst all parameters tended to decrease with 
increasing noise. The accuracy o f estimating To and Tc increased with increasing 




To evaluate the utility o f CT-Perfusion software in assessing changes in a rat 
model fibrotic liver disease, we conducted a sensitivity analysis o f the Johson and 
Wilson model utilized by CT-Perfusion as well as performed Monte-Carlo simulations 
for normal, mild and severe disease conditions as outlined in Table 1.
In the Monte-Carlo simulations To estimates were very stable, showing little 
bias among all disease states and noise levels. As predicted by the covariance matrix 
the variance o f the estimate decreased with increasing disease level.
Monte-Carlo simulations for Tc showed a positive bias under the normal 
condition. Mild and sever disease conditions showed little bias. The correlation matrix 
showed a strong negative correlation between Tc and FT. In the Monte-Carlo 
simulations the estimates o f Ft was negatively biased for normal conditions. Thus, the 
Monte Carlo simulations demonstrate the strong negative correlation between Tc and 
Fj predicted by the covariance/correlation matrix. The variances o f  Tc and Ft in the 
Monte Carlo simulations also agreed with the predictions o f the covariance matrix, 
both decreased with increasing disease severity.
The Vb estimates in the Monte Carlo simulations were stable among disease 
states and noise levels. The mild diseased state had the largest bias but still remained 
less than 10% relative to the mean. The Vb estimates also had the smallest variance o f  
all the estimated parameters relative to their means. This is likely because o f  the
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strong negative correlation between Tc and FT. Since Vb is the product o f Tc and Fb 
according to the Central Volume Principle27,28, any error in one parameter would 
largely be canceled out by error in the other.
Determined by Ft and E via Crone’s equation 21, PS was the least stable and 
accurate o f all the parameters. This should not be surprising as the covariance matrix 
predicted a very large variance for the estimation o f PS. As the Monte-Carlo 
simulations demonstrate in Figure 2.4, constraints applied by CT Perfusion software 
greatly reduce this variance. Consequentially a large bias is introduced into the 
estimate. The changes in the sensitivity function o f E over disease severities were the 
largest among all the parameters (Figure 2.3 C). These changes in sensitivity also 
affect the parameters with which E is correlated. Under normal conditions E is 
partially correlated with Tc, but then becomes more closely correlated with a  and Ft 
as the disease severity worsens. These correlations mean that any bias in E will be 
transferred to the correlated parameters. Thus, bias in the estimate o f E, which is 
caused by constraints intended to reduce its variance in CT Perfusion, is a major 
source o f bias seen in the other parameters.
The covariance matrix showed no trend in the variance o f a , however, in the 
Monte-Carlo simulations the variance for a  increased as disease severity worsens. 
This is likely due to the physiological constraint that a  must be positive which is 
employed by CT-Perfusion. At low values o f a  this constraint will affect the estimate 
more than at the higher values. As a result the low a  (low disease severity) estimates 
have lower variance than predicted by the covariance matrix. Overall the Monte-Carlo 
simulations show a stable estimate o f a  with disease severity and noise levels.
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Variance, although increasing with disease severity, remained reasonable. The 
sensitivity function for a  shows a narrow temporal window o f sensitivity. Care should 
be taken that no motion or other artifacts occur during this window o f imaging or 
large errors in the estimation o f a  may result.
We conducted a sensitivity analysis o f the model utilized by CT-Perfusion, as 
well as performed Monte-Carlo simulations for different health conditions, both 
normal and abnormal, o f  the liver. The comparison o f the theoretical estimates o f  
variance from the covariance matrix to the results o f the Monte-Carlo simulations 
highlight some o f the effects o f constraints used in CT-Perfusion software. While 
constraining a variable can reduce its variance, this inevitably introduces a bias into 
the estimate. Whenever there is a high level o f correlation between parameters, 
caution should be used when applying constraints. Any bias introduced by a constraint 
will not only bias the constrained parameter, but can bias other correlated parameters 
as well.
There are limitations in this study. First, one set o f the arterial and the portal 
venous time density curves from a single DCE-CT rat study was used to generate the 
Monte-Carlo simulations as well as the sensitivity functions and covariance and 
correlation matrices. Second, the effects o f different noise levels o f  the input time 
density curves or injection rates were not investigated. The effect o f  different 
injection rates on compartmental models has been investigated several times before 14 
.I t  has been concluded that slowing down the injection rate generally increases 
uncertainty and bias in parameter estimation.
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Overall these simulations suggest that CT-Perfusion can accurately and 
reliably measure multiple physiological parameters in the liver o f the rat. One o f these 
parameters, a, being the ratio between the Fa and Ft, could be a sensitive parameter 
for non-invasively measuring fibrosis progression in the liver.
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Figure 2.1 Time density (concentration) curves o f the abdominal aorta, Ca(t), and 
the portal vein, Cpv(t), acquired from a DCE- CT study on a rat scanned at 120kVp
and 80mA.
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Figure 2.2 Schematic o f Jonson and Wilson model modified for dual input for the
liver. Contrast arriving from the hepatic artery Ca(t) and portal vein Cpv(t) flows into 
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Figure 2.3 Sensitivity functions for normal, mild, and severe disease conditions.
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Figure 2.4 Results from the Monte Carlo simulations. The bias is plotted on the 
vertical axis and standard deviation o f the added Gaussian noise on the horizontal axis. 
Error bars represent the standard deviation o f  the estimated parameter at each level o f
noise.
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Values Used For Sensitivity Analysis
a Fy E k To Tc vb PS
Normal 15 200 0.17 0.063 4.0 8.5 28.3 37.3
Mild 25 150 0.12 0.021 4.0 10.5 26.3 19.2
Severe 40 125 0.10 0.011 4.0 10.5 21.9 13.2
Table 2.1 Parameter values used for sensitivity analysis and Monte-Carlo
simulations. The values were determined form previous microsphere experiments and 
indicator dilution techniques. Units are as follows: a  %; Fj ml/min/lOOg; E unitless; k 





Variance as Predicted by the Covariance Matrix
<x(%) Ft E k To Tc vb PS
Normal SD=2 5.27 13.5 0.20 0.020 0.7 0.8 3.27 233.2
SD=4 10.5 26.9 0.40 0.039 1.4 1.6 6.55 466.3
SD=6 15.8 40.4 0.59 0.059 2.0 2.4 9.82 699.5
SD=8 21.1 53.9 0.79 0.078 2.7 3.2 13.1 932.7
Mild SD=2 5.89 8.95 0.16 0.008 0.5 0.7 2.42 197.1
SD=4 11.8 17.9 0.32 0.016 1.0 1.3 4.84 394.1
SD=6 17.7 26.8 0.47 0.024 1.5 2.0 7.26 591.2
SD=8 23.5 35.8 0.63 0.032 2.0 2.6 9.68 788.2
Severe SD=2 5.32 7.54 0.17 0.006 0.3 0.6 1.88 216.3
SD=4 10.6 15.1 0.35 0.012 0.7 1.1 3.76 432.6
SD=6 16.0 22.6 0.52 0.018 1.0 1.7 5.65 648.9
SD=8 21.3 30.2 0.69 0.024 1.3 2.3 7.53 865.2
Table 2.2 Variances o f estimated parameters for normal, mild, and severe liver
disease, as determined from the diagonal o f  the covariance matrix. Units are as





a Ft E k To Tc
a 1.000 0.027 0.137 -0.186 0.870 -0.147
Ft 0.027 1.000 0.264 0.222 0.476 -0.948
Normal E 0.137 0.264 1.000 0.883 0.224 -0.500K -0.186 0.222 0.883 1.000 -0.078 -0.360
To 0.870 0.476 0.224 -0.078 1.000 -0.554
Tc -0.147 -0.948 -0.500 -0.360 -0.554 1.000
a Ft E k To Tc
a 1.000 -0.623 0.576 0.310 0.793 0.322
Fy -0.623 1.000 -0.305 -0.116 -0.079 -0.895
Mild E 0.576 -0.305 1.000 0.908 0.511 -0.086K 0.310 -0.116 0.908 1.000 0.306 -0.173
To 0.793 -0.079 0.511 0.306 1.000 -0.232
Tc 0.322 -0.895 -0.086 -0.173 -0.232 1.000
a Ft E k To Tc
a 1.000 -0.748 0.690 0.511 0.570 0.420
Ft -0.748 1.000 -0.534 -0.380 0.018 -0.861
Severe E 0.690 -0.534 1.000 0.939 0.425 0.110K 0.511 -0.380 0.939 1.000 0.330 0.027
To 0.570 0.018 0.425 0.330 1.000 -0.364
Tc 0.420 -0.861 0.110 0.027 -0.364 1.000
Table 2.3 Correlation matrices o f  estimated parameters for normal, mild, and 
severe liver disease. Elements o f  the correlation matrix are all between -1 and 1. 
Unity represents perfect positive correlation and -1 is perfect negative correlation. A  
coefficient o f zero represents no correlation.
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CHAPTER3
IN-VIVO MONITORING OF THE DEVELOPMENT AND PROGRESSION 
OF HEPATIC FIBROSIS IN A CCL, RAT MODEL WITH CT PERFUSION
3.1 INTRODUCTION
With an increased understanding o f the mechanism o f fibrosis in response to 
chronic liver injury1, potential anti-fibrotic drugs have been proposed and 
demonstrated the reversal o f  liver fibrosis in-vitro and in-vivo2 3 4. To effectively test 
these drugs, both in animals and eventually in clinical trials, a repeatable measure o f  
fibrosis progression will be required.
The staging o f fibrosis is also an important factor in treatment planning. 
Patients with hepatitis C virus have been shown to benefit from antiviral therapy
r  /  *7however; interferon treatment is not without its complications . Thus, therapy is 
reserved for those who have already shown a marked progression o f liver disease. 
Currently patients with a METAVIR score o f F2 or F3 are classified as having 
‘clinically significant’ fibrosis meaning they are at higher risk for developing cirrhosis 
and it’s subsequent complications. Thus, patients with clinically significant fibrosis 
have a higher indication for anti-viral treatment than patients with no, or minimal 
fibrosis (METAVIR F0/F1) 9 l0. Patients with the highest METAVIR score o f  F4 
should be monitored and treated for cirrhosis related complications such as, portal 
hypertension and hepatocellular carcinoma.
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Liver biopsy is currently the gold standard for assessing fibrosis, however it is 
not without limitations. Histological grading is not reproducible; there are both intra- 
and inter-observer variability on small sized or fragmented biopsy samples11. In 
addition the biopsy procedure can be painful and carries a risk o f serious 
complications , greatly reducing patients’ willingness to participate in clinical trials. 
Because o f these limitations, biopsy is an impractical method for the regular 
monitoring o f liver fibrosis required for the evaluation o f new anti-fibrotic treatments 
as well as treatment planning.
In response to this need, many noninvasive methods for monitoring hepatic 
fibrosis have been proposed; o f which the most thoroughly investigated is serum 
markers. Both direct serum markers, such as hyaluronate, and indirect serum markers 
such as alanine transaminase (ALT) and aspartate transaminase (AST) have been 
investigated 13 14 15 16 I7. When only direct or indirect markers are used individually 
they can reasonably diagnosis or exclude cirrhosis but lack the ability to differentiate 
intermediate stages o f  fibrosis. Thus newer algorithms, combining multiple markers, 
such as Fibrotest or the Enhanced Liver Fibrosis (ELF) test have been proposed to 
improve diagnostic accuracy. In a meta-analysis Fibrotest was able to distinguish 
between METAVIR stages ^F1 vs or ‘clinically significant’ fibrosis with 
AUROC o f .84 .A  limitation o f direct liver markers is that they are not liver specific 
thus; they require patient specific considerations to be taken into account when 
interpreting the results. Currently, the ability to measure direct markers is not 
routinely available in most hospitals.
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Non-invasive imaging methods for staging o f liver fibrosis have been 
proposed as well. Some o f these include, diffusion-weighted magnetic resonance 
(MR) , liver stiffness measurement (LSM) techniques such as transient
elastography22,23 and MR elastography24 25 26, as well as perfusion imaging 27'29.
The goal o f perfusion imaging in the liver is to track changes in the hepatic 
microvasculature. Chronic liver disease, regardless o f the etiology, leads to the 
“activation” o f hepatic stellate cells30. This activation results in the transition o f  the 
quiescent hepatic stellate cells to a proliferative, fibrogenic, and contractile 
myofibroblast-like phenotype. The contractility o f the activated hepatic stellate cells, 
as well as the resulting fibro-genesis and collagen deposition, disrupts the normal 
sinusoidal vasculature. Consequentially, an increase in blood flow resistance is 
observed leading to decreased portal blood perfusion and portal hypertension31.
In this regard the aim o f our study was to correlate the perfusion parameters 
calculated using CT-Perfusion (GE Healthcare) in the liver o f the rat, to the amount of  
liver fibrosis determined by digital image analysis o f  stained excised liver sections.
3.2 METHODS
3.2.1 Animal Model
Male Sprague-Dawley rats (300g - 350g) were randomized into control and 
treated groups. To induce liver cirrhosis, the treated group (n=9) received 
intraperitoneal injections o f carbon tetra-chloride (CCI4) three times a week at a dose 
o f 0.15ml/kg diluted 1:6 in olive oil. Phénobarbital (0.04g/L) was also added to the
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drinking water o f the CCI4 treated animals to further potentiate liver damage 32. The 
control group (n=6) received intraperitoneal saline injections three times a week. 
Dynamic contrast enhance computed tomography (DCE-CT) scans, as described 
below, were performed on all animals at baseline and after 2, 4, 6, and 8 weeks of 
treatment. After 8 weeks o f treatment all animals were euthanized. Livers were 
removed and fixed in 10% buffered formalin for histological examination.
To obtain histology samples at intermediate disease levels two groups o f  rats 
were treated with CCI4 and phénobarbital as described above. The first group (n=5) 
received treatment for 4 weeks and the second group (n=5) received treatment for 6 
weeks. After the respective 4 and 6 weeks o f treatment, DCE-CT scans were 
performed. The animals were then euthanized and livers were removed for 
histological analysis.
3.2.2 Animal Preparation
Animals were initially sedated with 3% isoflurane. Once sedated, a catheter was 
inserted into the tail vein. 35mg/kg o f pentobarbital was then administered via intra­
venous (IV) injection and isoflurane anesthesia was discontinued. Animals were then 
intubated and placed in a supine position o f  the CT bed where they were mechanically 
ventilated on oxygen at a rate o f approximately 80 breaths per minute. To facilitate a 
breath hold, 0.1ml/kg o f the paralytic, pancuronium, was administered IV just prior to 
imaging. CO2 and O2 levels were monitored using a pulse oximeter. PCO2 was 
maintained at 40+/-2 mm Hg and O2 saturation was maintained above 98%. 
Temperature was monitored via rectal probe and maintained at 37.5 +/- 0.5C with a
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re-circulating heated water blanket. Supplemental doses (5mg/kg) o f pentobarbital 
were administered IV as required during the experiment.
3.2.3 Imaging
DCE-CT scans were performed using a clinical GE multi-slice CT scanner 
(Discovery VCT, GE Healthcare). A localization scan was first performed to place 
eight 5mm slices covering the entire liver. After the scan location was selected the 
DCE-CT scan was conducted in two phases. In the first phase, images were acquired 
in cine mode with a tube voltage and current o f  120kVp and 80mA respectively and a 
gantry speed o f one rotation per second. Images were reconstructed using the detail 
filter and a temporal resolution o f 0.45 seconds. Total time for the first phase cine 
scan was 34 seconds. At the beginning o f  the scan lml/kg o f an iodinated contrast 
agent (Omnipaque 300mgl/ml) was injected via the tail vein catheter over 4s. During 
the entire first phase the ventilator was turned off to simulate a breath hold and 
eliminate any respiratory motion in the liver.
In the second phase the ventilator was turned on (80 breaths per minute) and 
animals were scanned in cine mode for 1.2 seconds, every 10 seconds, up to a total o f  
two minutes. After completion o f the scan, images from the second phase were 
retrospectively gated to match the first phase images. Using the first phase images, a 
region o f interest was drawn at the level o f the diaphragm. From the 16 images in each 
o f  the second phase cine scans, the image that best matches the first phase images 
(acquired with breath hold) was manually selected based on image intensity. This 
proved to be a simple manual registration requiring only a few minutes to complete
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per study. The smooth second phase o f the portal venous and aortic time density 
curves demonstrate the aptitude o f the retrospective gating method (Figure 3.1).
3.2.4 CTPerfusion Measurements/Data Analysis
CT images were analyzed using CT Perfusion software, which utilizes a dual 
input hybrid, compartment and distributed parameter, model. This model has been 
previously described and validated with microspheres in the rabbit liver 33. As 
expressed in equation (1), a weighted sum o f the aortic, Ca(t), and portal venous, 
Cpv(t), time density curves (TDC) were deconvolved against the liver parenchyma 
TDC, Q(t), in CT Perfusion (GE Healthcare) on a pixel-by-pixel basis to obtain the 
impulse residue function (IRF) 34 35 from which hepatic hemodynamic parameters are 
derived as explained below. The abdominal aorta was used as a surrogate for the 
hepatic artery due to its small size. Equation (2) defines the IRF, R(t)
that is derived from the hepatic artery and thus, the hepatic arterial blood flow (Fa) is 
calculated as a-Fj. E is the extraction fraction o f the contrast agent to the extra 
vascular space, k is the net back flow rate o f  the contrast from the extravascular space
( 1)
0.0 0 < t < T0
R(t) = « 1.0 T0 < t < T 0 +Tc
Ee-k(«-T0-Tc) t > T0 + Tc
(2)
Ft is the total hepatic blood flow, a  is the fraction o f total hepatic blood flow
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to the intravascular space defined as k= FyE/Ve, where Ve is the extra vascular 
volume. Tc is the mean transit time o f the contrast agent from the arterial side to the 
venous side. To is the appearance time o f the contrast agent in the parenchyma relative 
to that o f  the aorta. Blood volume (Vb) is calculated as the product F rT c via the 
Central Volume Principle. The permeability surface area product (PS) is calculated 
from the Crone relationship as P S = -F rln (l-E )36.
Perfusion weighted (PW) maps were generated for each CT-Perfusion study by 
averaging the images in the first phase o f each scan. In the PW maps the hepatic artery 
and portal vein branches appeared hyper-dense while the hepatic veins appeared hypo- 
dense. Using custom software (IDL v6.0; RSI Inc., CO, USA) a region o f interest 
(ROI) was drawn on each PW map to encompass as much liver parenchyma as 
possible while avoiding large vessels. Measurements were obtained by applying the 
set o f  liver ROIs for each study to its respective functional maps (Ft, Fa, a , Vb, Tc, PS) 
generated by CT-Perfusion.
3.2.5 Histological Analysis
After the final CT examination, rats were sacrificed with sodium pentobarbital 
overdose. Livers were removed and fixed in 10% buffered formalin. Multiple liver 
lobes were collected and embedded in paraffin and 5 pm thick slices were obtained for 
histological analysis. The slices were then stained with methyl blue and mounted on 
slides. The slides were digitized using an Aperio Scan Scope system (Aperio 
Technologies Inc., Vista, Ca, USA). Twelve images with an individual area o f  
approximately 5mm were collected over multiple liver lobes o f each rat. The ImageJ
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software package 37 was used to measure percent positive area o f stained collagen 
(PPAC). Thresholds were automatically determined using the maximum entropy 
method . An example o f a fibrotic liver stained with methyl blue is shown in Figure 
3.3(A) and the resulting PPAC determined with Image J in Figure 3.3(B).
3.2.6 Statistical Analysis
Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, 
IL, USA). A Mixed Model ANOVA was used as an omnibus test to identify 
significant differences between the control and CC14 treated groups. Student t-tests 
with Bonferroni correction were used for post-hoc analysis o f differences. To assess 
differences in PPAC between control rats and rats treated with CC14 for 4, 6 and 8 
weeks, independent unpaired t-tests for unequal variances were used. The Spearman 
correlation method was used to evaluate the relationship between the PPAC and a. A 
P-value <0.05 was regarded as statistically significant.
3.3 RESULTS
CT imaging and subsequent analysis was successfully performed in all animals 
at all time points. None o f the rats suffered any obvious adverse effects from the CC14 
treatment nor did they develop any complication such as acities.
Liver samples in 3 animals (one treated with CC14 for 6 week and 2 treated 
with CCL4 for 8 weeks) were not adequately fixed and thus, subsequent staining and 
digital image analysis could not be performed. For the other 22 rats (6 treated with
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saline for 8 weeks and 6, 5, 8 treated with CC14 for 4, 6, and 8 weeks respectively) 
PPAC was quickly and easily assessed. The mean PPAC for saline treated animals 
was 0.37%. The mean PPAC for animals treated with CC14 was as follows; four 
weeks o f treatment, 1.74%; 6 weeks o f treatment, 2.31%; eight weeks o f treatment, 
2.20%. The PPAC o f animals treated with CC14 for 4, 6 and, 8 weeks were all 
significantly higher than controls (P<0.002). However weeks 4, 6 and, 8 were not 
significantly different from each other.
Figures 3.4 through 3.9 show measurements o f  Ft, Fa, a , Vb, Tc, and PS 
respectively over 8 weeks o f treatment with either saline (control) or CC14 (treated). 
The mixed model analysis showed that CC14 treatment had a significant effect on Ft, 
Fa, a , and Vb but not Tc. PS showed a non-significant trend o f increase with time in 
the treated group
Post hoc analysis using a two-tailed student t-test with Bonferroni correction 
showed significant differences in F t , Fa, a , and Vb between control and treated 
animals. There was a significant difference in Ft between control and CC14 treated 
animals at weeks 6 and 8, as well as between CC14 treated animals at week 0 
(baseline) and week 8. Fa showed a significant difference between treated and control 
animals at week 6. a  showed a significant difference between control and CC14 
treated animals at weeks 4, 6 and, 8. a  o f CC14 treated animals at weeks 4, 6, and 8 
were also significantly higher from the baseline value. Vb for CC14 treated animals at 
week 8 was significantly lower than baseline value and that o f control animals at week
8.
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A substantial correlation (r=.82 p<.00001) was observed between a  and PPAC 
and is shown in Figure 3.10. All other perfusion parameters showed a low (r < 0.5) 
correlation with PPAC.
3.4 DISCUSSION
Digital image analysis was used in this study as a quantitative method for 
assessing liver fibrosis in excised liver sections. The common histopathological
Omethods o f assessing fibrosis has been the METAVIR staging system . METAVIR 
was designed for the prognostic evaluation o f biopsy from hepatitis C patients. 
Categorical staging methods place a larger emphasis on the patterns and structures 
present than the actual extent o f fibrosis and are thus limited by their semi-quantitative 
nature as well as inter-observer variability. In contrast to this, digital image analysis 
uses a continuous variable and has implicitly high reproducibility and accuracy39.
Of all the perfusion parameters only a  showed a strong correlation (r=0.82 
PO.OOOOl) with PPAC (Figure 3.10). The increase in a  is caused by the hepatic 
arterial buffer response (HABR). As resistance to blood flow increases with collagen 
deposition as fibrosis progresses, portal blood flow has been shown to decrease. It is 
suspected that decreased washout o f adenosine, a vasodilator, caused by decreased 
portal blood flow mediates an increase in hepatic arterial blood flow31. Thus, a , which 
is the ratio o f Fa/Fr, increases with disease severity and may potentially be an
excellent biomarker for liver fibrosis.
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The CC14 model o f liver fibrosis used in this study is common and has been 
well explored 40. Over the 8 weeks o f treatment, liver fibrosis progressed from normal 
liver architecture to portal fibrosis with few septae and finally bridging fibrosis and 
cirrhosis (Figure 3.3). Only three o f the treated animals developed cirrhosis. Although 
Ft and Vb did not correlate well with PPAC treated animals had significantly lower 
values than control animals after 8 weeks o f treatment. While a  seems to be a good 
biomarker for moderate fibrosis, Fj and Vb may be good biomarkers for predicting 
cirrhosis which was starting to develop in our model. Other perfusion studies o f  
cirrhotic liver disease have found similar decreases in Ft and Vb41,42. Multiple 
biomarkers o f different stages o f  liver disease may be useful for staging. Similar to 
serum marker algorithms, combinations o f perfusion parameters could improve 
diagnostic performance and warrant further investigation.
The use o f mechanical ventilation along with a paralytic agent allowed for a 
simulated breath hold in the animal. Along with a simple and fast manual registration 
technique almost all motion was eliminated from the cine scan. While this 
methodology cannot be used in patients, novel registration methods have the potential 
to substantially reduce breathing motion and noise respectively in clinical practice43.
In our study the histological samples were not precisely matched to the 
location o f perfusion analysis. Although liver disease is generally thought o f as a 
diffuse disease, some heterogeneity has been shown to occur". Thus, correlation of  
PPAC and perfusion parameters may have been improved if  an exact match between 
the area analyzed at CT examination and histological samples could be obtained.
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DCE-CT imaging carries with it the inherent risks o f cancer 
induction/mortality and nephrotoxicity from ionizing radiation and iodinated contrast 
agents used in the study. Repeated imaging o f the same location required for DCE 
imaging techniques can lead to high effective doses o f typically 15-20 mSv in 
patients. However, newer iterative reconstruction techniques can reduce the effective 
dose by several fold. 44 45
DCE-MR offers a solution to radiation dose but has it’s own drawbacks. 
Compared to DCE-CT, DCE-MR has a lower spatial resolution. Additionally, 
velocity-induced signal intensity changes in larger vessels has created difficulties 
in obtaining quantitative perfusion data with DCE-MR 46 47.
For this study we used a commercially available dual input hybrid, 
compartment and distributed parameter, model (CT-Perfusion, GE Healthcare, 
Waukesha,WI, USA). Several different methods for the measurement o f liver 
perfusion have previously been proposed 48 29. However, discrepancies between 
models used for perfusion analysis have been demonstrated 49. Choice o f method for 
the estimation o f perfusion parameters must be assessed for each application. Models, 
and respective assumptions, must be applicable to the physiology o f both the normal 
and disease states. Ideally, in-vivo validation o f perfusion parameters against a non­
model based gold standard would allow quantitative evaluation o f various models. To 
this effect, microspheres have been used to validate hepatic arterial and portal venous 
blood flow in the liver 33 29. While these methods allow validation o f blood flow other 
perfusion parameters such as blood (or distribution) volume, Tc and PS currently lack 
a strong reference standard for validation. Until all perfusion parameters can be
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reliably validated, under normal and disease states, the utility o f various models will 
depend largely on their diagnostic capability and availability.
In conclusion this study showed that perfusion parameters estimated with CT- 
Perfusion correlated with fibrosis content determined by digital image analysis. In 
particular, a , correlated very well (r=0.82 PO.OOOOl) with the progression o f fibrosis 
and significant changes in Ft and Vb were observed when rats progressed to cirrhosis. 
These result show that CT-Perfusion is a useful method for quantifying hepatic 
fibrosis and subsequent progression to cirrhosis.
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Figure 3.1 Concentration time curves from the abdominal aorta, Ca(t), and the 
portal vein, Cpv(t), acquired from actual CT data o f a rat. The smooth nature o f the 
second phase demonstrates the aptitude o f the registration method used.
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C o n tro l  4 W e e k s  C C I 4  8 W e e k s  C C I 4
Figure 3.2 Example o f Regions O f Interest (ROI) drawn for measurement o f  
perfusion parameters. Care was taken to include as much liver parenchyma as possible 
while excluding large vessels. Histology was stained with methyl blue for collagen. 
Decreased hepatic blood flow (Ft) and blood volume (Vb) can been seen after 8 weeks 
o f treatment. And increase in arterial fraction o f blood flow (a) can be seen after only
4 weeks o f  treatment.
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Figure 3.3 An example o f quantification o f liver fibrosis with digital image 
analysis. Sample image used for quantification (top) and 8-bit converted imaged for 
digital image analysis (bottom). Red area corresponds to the percent positive area o f  
collagen (PPAC). In this example PPAC was 2.9% o f the total area.
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Weeks of Treatment
Figure 3.4 Total hepatic perfusion measured in rats treated with CCI4 and saline 
over 8 weeks o f treatment. (*significant difference from treated baseline; #significant 
difference from control)
0 2 4 6 8
Weeks of Treatment
Figure 3.5 Hepatic arterial blood flow measured in rats treated with CCI4 and 
saline over 8 weeks o f treatment. (* significant different from treated baseline)
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Figure 3.6 Hepatic arterial fraction o f blood flow measured in rats treated with 
CC14 and saline over 8 weeks o f treatment. (*significant difference from treated 
baseline; #significant difference from control)
Weeks of Treatment
Figure 3.7 Blood volume measured in rats treated with CCI4 and saline over 8 
weeks o f treatment, (♦ significant difference from treated baseline; #significant 
difference from control)
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Figure 3.8 Mean vascular transit time measured in rats treated with CCU and 
saline over 8 weeks o f treatment.
Weeks of Treatment
Figure 3.9 Permeability surface area measured in rats treated with CCI4 and saline
over 8 weeks o f treatment.
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Figure 3.10 Correlation between hepatic arterial fraction and percent positive area 
o f collagen (PPAC) from digital image analysis o f  liver specimens. Spearman 
correlation coefficient, r=0.82 PO.OOOOl.
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CHAPTER 4
SUMMARY AND FUTURE WORKS
4.1 SUMMARY
The primary objective o f this thesis was to evaluate the utility o f  dynamic 
contrast enhanced computed tomography (DCE-CT) imaging in conjunction with CT 
Perfusion (GE Healthcare) for the investigation o f fibrotic liver disease. Monte Carlo 
simulations and sensitivity analysis were used to characterize the bias, variance and 
covariance o f perfusion parameters calculated with CT Perfusion. DCE-CT scans 
were performed bi-weekly on rats treated with peritoneal injections o f CC14 to induce 
liver fibrosis and, by eight weeks o f treatment, cirrhosis. Sham injected (control) rats 
were similarly imaged for comparison. The perfusion parameters: total hepatic blood 
flow ( F t ) ,  hepatic arterial blood flow (Fa), blood volume (V b ) , mean vascular transit 
time (Tc), hepatic arterial fraction o f blood flow (a), and permeability surface area 
(PS), were then derived from the DCE-CT scans using CT Perfusion. As treatment 
progressed, CC14 treated rats showed significant changes in perfusion parameters. 
Histological samples stained with methyl blue were collected at various stages of 
treatment. From these stained samples liver fibrosis was quantified with digital image 
analysis and correlated to perfusion parameters. A strong correlation was found 
between fibrosis content and hepatic arterial fraction o f blood flow (a).
The next sections summarize results obtained in each set o f experiments 
completed in this thesis; followed by a discussion o f the experimental and clinical
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relevance o f all major findings. Monte Carlo simulations demonstrated reasonable 
bias and variance in perfusion parameter estimates. In addition we were able to 
illustrate significant changes in FT, Vb, Fa, and a  as fibrosis progressed in a CCI4 rat 
model. This demonstrates the ability o f  DCE-CT imaging with CT Perfusion to 
quantitatively assess changes associated with vascular changes known to occur during 
the development o f cirrhosis . The chapter concludes with a discussion on potential 
avenues o f further research.
4.2 ERROR ANALYSIS OF HEPATIC PERFUSION PARAMETERS 
CALCULATED WITH CT PERFUSION
Chapter 2 presents the results o f  the sensitivity analysis o f perfusion parameters 
estimated with CT Perfusion software. Results o f the Monte Carlo simulations are 
presented for normal, mild, and severe stages o f  liver fibrosis. All sensitivity and 
Monte Carlo simulations were conducted using hepatic arterial and portal venous 
input functions obtained from actual DCE-CT studies on rats. Sensitivity analysis 
showed that Ft was the most sensitive parameter followed by a , k, E, Tc, and To 
respectively. Subsequent calculation o f the correlation matrix showed high correlation 
between Ft and Tc. Monte Carlo simulations showed that the accuracy o f parameter 
estimation amongst all parameters tended to decrease with increasing noise.
To and Vb showed little change in bias for both increasing noise and disease 
severity. Bias remained stable for Tc and Ft estimates for the mild and severe disease 
states but increased with noise for the normal disease state. The accuracy of
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estimating To and Tc increased with increasing disease severity.
An interesting observation was the effect o f constraints imposed by CT 
Perfusion software on the parameter estimates. These constraints imposed a bias on 
the parameter estimates, as could be seen in the Monte Carlo simulations. Of 
particular note, the bias over varying disease levels was inconsistent for Ft, Tc, and 
PS. This inconsistent bias could affect the ability to measure changes in perfusion 
parameters as liver disease progresses. Other parameter estimates such as Vb and a  
were accurate and consistent among all levels o f disease severity.
4.3 IN-VIVO MONITORING OF THE DEVELOPMENT AND 
PROGRESSION OF HEPATIC FIBROSIS IN A CC14 RAT MODEL WITH CT 
PERFUSION
Chapter 3 presents a study tracking changes in perfusion parameters in a CCI4 
rat model o f liver fibrosis. Animals were randomized into control (n=6) and CCI4 
treated (n=9) groups. Dynamic contrast enhance computed tomography (DCE-CT) 
scans were performed on all animals at baseline and after 2, 4, 6, and 8 weeks o f 
treatment. After 8 weeks o f treatment all animals were euthanized and livers were 
removed and stained for fibrosis with methyl blue. To obtain histology samples at 
intermediate levels o f progression two additional groups o f rats were treated with 
CCI4. The first group (n=5) received treatment for 4 weeks and the second group 
(n=5) received treatment for 6 weeks. DCE-CT scans were performed in these two 
shorter treatment groups at the same time points as the first, 8-week treatment, group,
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animals were euthanized and livers were removed for histological analysis at the end 
o f  experiment.
The DCE-CT scans were analysed with CT Perfusion software and the 
perfusion parameters, Fj, Fa, Vb, Tc, a , and PS were measured. Mixed model analysis 
showed that CCI4 treatment had a significant effect on Ft, Fa, a , and Vb but not Tc or 
PS. Post hoc analysis using a two-tailed student t-test with Bonferroni correction 
showed significant differences in F t , Fa, a , and Vb between control and treated 
animals. Digital image analysis was used to measure percent positive area o f stained 
collagen (PPAC). A substantial correlation (r=.82 p<.00001) was observed between a  
and PPAC. All other perfusion parameters showed a low (r < 0.5) correlation with 
PPAC. The strong correlation between a  and PPAC suggests that a  is a sensitive 
biomarker o f fibrosis progression in the liver. CT-Perfusion proved to be an effective 
tool for tracking known vascular changes associated with the development o f cirrhosis 
in an animal model.
4.4 EXPERIMENTAL AND CLINICAL RELEVENCE
t
The studies completed in this thesis have a number o f implications 
experimentally. In the first study the variance, bias and correlation o f perfusion 
parameters calculated with CT Perfusion were characterized for the analysis o f  liver 
disease. Results o f this study are applicable to the interpretation o f rat and possibly 
patient liver DCE-CT studies analyzed with CT Perfusion.
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In the second study a CT imaging method for measuring changes in perfusion 
parameters in a CCI4 rat model o f liver fibrosis was developed. Because o f the non- 
invasive nature o f the imaging method, repeat measurements can be made in the same 
subject. Furthermore, the CT hardware and relevant software used are widely 
available. The ability o f CT Perfusion to rapidly and accurately assess tissue 
hemodynamics makes the methodology developed in this thesis useful for 
investigating liver diseases involving vascular changes o f the liver. Of particular note 
would be cancer and ischemia/reperfusion injury in pre-clinical models.
The methods used in this thesis could be readily advanced to clinical use. The 
DCE-CT scanning protocol used the combination o f a paralytic and a ventilator, 
allowing for a simple registration method to reduce motion and noise in the data set. 
This methodology is impractical in the clinical setting however, registration 
techniques and iterative reconstruction methods currently under development4 5 could 
sufficiently reduce noise to acceptable levels. Radiation dose would not be a barrier to 
clinical implementation. DCE-CT imaging results in an effective dose to the subject 
of 15-20 mSv which, is similar to current clinical three-phase liver scans6.
4.5 FUTURE WORKS
The presented studies show the potential o f  using DCE-CT with CT Perfusion 
to longitudinally follow hemodynamic changes associated with the progression o f  
fibrotic liver disease. With an increased understanding o f the mechanisms o f fibrosis,
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nnew treatment options are becoming available . Future studies could use the methods 
developed in this thesis to aid in the assessment o f potential anti-fibrotic treatments.
OCT Perfusion has also been effectively used to study cancers o f the liver . 
Since 80% o f hepatocellular carcinoma (HCC) occur in a cirrhotic background 9 a 
cirrhosis/HCC model would be o f particular interest. A Dimethylnitrosamine model is 
capable o f producing fibrosis and cirrhosis in rats and eventually HCC 10. The 
methods developed in this thesis would be ideal for studying such a model, as well as 
evaluating potential anti-angiogenic treatments on both the development o f cirrhosis 
and HCC.
4.6 LIMITATIONS
There are a few limitations to these studies. Parameters used for simulation 
and sensitivity analysis were only appropriate for the study o f rat liver. The results 
can not be applied to studies in humans or other animal models where hepatic 
perfusion parameters differ.
Histological samples were not precisely matched to the location o f perfusion 
analysis. Although liver disease is generally thought o f as a diffuse disease, some 
heterogeneity has been shown to occur 11. Thus, correlation o f PPAC and perfusion 
parameters may have been improved if  an exact match between the area analyzed at 
CT examination and histological samples could be obtained.
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Although the CCI4 rat model o f  liver fibrosis is commonly used and well 
understood it has no direct human counterpart. The changes in perfusion parameters 
noted in the CCI4 model may differ in alternative models o f liver disease.
4.7 CONCLUSIONS
The most significant conclusions o f this thesis are listed below:
1) DCE-CT with CT Perfusion can track changes in hepatic hemodynamics 
associated with the development o f fibrotic liver disease.
2) The hepatic arterial fraction o f blood flow is strongly correlated with liver 
collagen content in a CCI4 rat model o f  liver fibrosis.
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APPENDIX A
Jan uary 29, 2007
"This  is the Original A pproval for this protocol*
*A Full Protocol submission will be required in 2011*
Dear Dr. Lee:
Your Animal Use Protocol form entitled:
Perfusion and Lipid Imaging with a Liver Specific C T  Contrast Agent to Detect Progression of Cirrhosis 
Funding Agency CIHR - applied for
has been approved by the University Council on Animal Care. This approval is valid from January 29, 2007 to 
January 31, 2008. The protocol number for this project is #2007-02jMi and replaced #2005-051-07 (pilot).
1. This number must be indicated when ordering animals for this project
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the project, request that an internal 
scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the A C V S  office. Health 
certificates will be required.
A N IM A L S  A P P R O V E D  FO R  1 YR.
Species Strain O ther Detail
Pain
Level
Anim al # Total 
for 1 Year
Rat Sprague Dawley -2 0 0  gm Male C 16
S TA N D A R D  O P E R A TIN G  P R O C E D U R E S
Procedures in this protocol should be carried out according to the following SOPs. Please contact the Animal Use 
Subcommittee office (661-2111 ext. 86770) in case of difficulties or if you require copies.
SO P's are also available at htto://www.uwo.ca/animat/acvs 
310 Holding Period Post-Admission
320 Euthanasia
321 Criteria for Early Euthanasia/Rodents
330 Post-Operative Care/Rodent \
343 Surgical Prep/Rodent/Recovery Surgery
R EQ U IR EM EN TS /C O M M EN TS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar 
with the contents of this document.
c.c. Approved Protocol 
Approval Letter
V/
The University of Western Ontario 
Animal Use Subcommittee/University Council on Animal Care 
Health Sciences Centre • London. Ontario • CANADA - N6A 5C1
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02 .01.2010
*This is the 3rd Renewal of this protocol
*A Full Protocol submission will be required in 01.31.2011
Dear Dr. Lee
Your Animal Use Protocol form entitled:
Perfusion and lipid imaging with a liver specific C T  contrast agent to detect progression of 
cirrhosis
has had its yearly renewal approved by the Animal Use Subcommittee.
This approval is valid from 02.01.2010 to 01.31.2011 
The protocol number for this project remains as 2007-028
1. This number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the project, request that an internal 
scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the ACVS office. Health 
certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar 
with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with institutional safety 
standards and have received ai! necessary approvals. Please consult directly with your 
institutional safety officers.
c.c.
The University o f  Western OntarioAnimal Use Subcommittee / University Council on Animal Care Health Sciences Centre, • London, Ontario • CANADA -N6A 5C1
